Anti-BCMA CART cells in relapsed and refractory multiple myeloma.

"At a median follow-up of 18.6 months, the median progression-free survival was 13.3 months in the ide-cel group, as compared with 4.4 months in the standard-regimen group (hazard ratio for disease progression or death, 0.49; 95% confidence interval, 0.38 to 0.65; P<0.001). A response occurred in 71% of the patients in the ide-cel group and in 42% of those in the standard-regimen group (P<0.001); a complete response occurred in 39% and 5%, respectively."

#Immunology #immunotherapy #CARTcells #MultipleMyeloma

https://www.nejm.org/doi/full/10.1056/NEJMoa2213614?query=featured_home